Cargando…

Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the current coronavirus disease 2019 (COVID-19) pandemic. A major virulence factor of SARS-CoVs is the nonstructural protein 1 (Nsp1), which suppresses host gene expression by ribosome association. Here, we show t...

Descripción completa

Detalles Bibliográficos
Autores principales: Thoms, Matthias, Buschauer, Robert, Ameismeier, Michael, Koepke, Lennart, Denk, Timo, Hirschenberger, Maximilian, Kratzat, Hanna, Hayn, Manuel, Mackens-Kiani, Timur, Cheng, Jingdong, Straub, Jan H., Stürzel, Christina M., Fröhlich, Thomas, Berninghausen, Otto, Becker, Thomas, Kirchhoff, Frank, Sparrer, Konstantin M. J., Beckmann, Roland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402621/
https://www.ncbi.nlm.nih.gov/pubmed/32680882
http://dx.doi.org/10.1126/science.abc8665
Descripción
Sumario:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the current coronavirus disease 2019 (COVID-19) pandemic. A major virulence factor of SARS-CoVs is the nonstructural protein 1 (Nsp1), which suppresses host gene expression by ribosome association. Here, we show that Nsp1 from SARS-CoV-2 binds to the 40S ribosomal subunit, resulting in shutdown of messenger RNA (mRNA) translation both in vitro and in cells. Structural analysis by cryo–electron microscopy of in vitro–reconstituted Nsp1-40S and various native Nsp1-40S and -80S complexes revealed that the Nsp1 C terminus binds to and obstructs the mRNA entry tunnel. Thereby, Nsp1 effectively blocks retinoic acid–inducible gene I–dependent innate immune responses that would otherwise facilitate clearance of the infection. Thus, the structural characterization of the inhibitory mechanism of Nsp1 may aid structure-based drug design against SARS-CoV-2.